Výsledky vyhledávání - "Derek J, Nunez"

Akademický článek

Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.

Autor: Rebecca J Hodge, Mark A Paulik, Ann Walker, Joyce A Boucheron, Susan L McMullen, Dawn S Gillmor, Derek J Nunez

Publikováno v: PLoS ONE, Vol 11, Iss 4, p e0153151 (2016)

BACKGROUND:Nutritional agents have modest efficacy in reducing weight and blood glucose in animal models and humans, but combinations are less well characterized. GSK2890457 (GSK457) is a combination of 4 nutritional agents, discovered by the systema

Externí odkaz: https://doaj.org/article/25304503342f4552b312335dff016388

Zobrazit plný text záznamu

Akademický článek

A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature.

Autor: Ali Abbasi, Anna-Stina Sahlqvist, Luca Lotta, Julia M Brosnan, Peter Vollenweider, Philippe Giabbanelli, Derek J Nunez, Dawn Waterworth, Robert A Scott, Claudia Langenberg, Nicholas J Wareham

Publikováno v: PLoS ONE, Vol 11, Iss 10, p e0163721 (2016)

Blood-based or urinary biomarkers may play a role in quantifying the future risk of type 2 diabetes (T2D) and in understanding possible aetiological pathways to disease. However, no systematic review has been conducted that has identified and provide

Externí odkaz: https://doaj.org/article/0f75ca42df7448358b10c54f68c508dc

Zobrazit plný text záznamu

Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials

Autor: Dawn Waterworth, Nicholas Galwey, Gurparkash Singh, Geert Byttebier, William Alazawi, Elisa Fabbrini, Derek J. Nunez, Bart Vannieuwenhuyse, Laura M. Yerges-Armstrong, Gary Meininger, Stuart Kendrick, Myriam Alexander, Lars Wallentin, Naveed Sattar, Ele Ferrannini, Harvey D. White

Publikováno v: American Journal of Physiology-Gastrointestinal and Liver Physiology. 316:G372-G386

Liver enzyme concentrations are measured as safety end points in clinical trials to detect drug-related hepatotoxicity, but little is known about the epidemiology of these biomarkers in subjects without hepatic dysfunction who are enrolled in drug tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc0b65807f014fd77e100c0045be2113
https://doi.org/10.1152/ajpgi.00051.2018

Zobrazit plný text záznamu

Akademický článek

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

Autor: Antonella Napolitano, Sam Miller, Andrew W Nicholls, David Baker, Stephanie Van Horn, Elizabeth Thomas, Deepak Rajpal, Aaron Spivak, James R Brown, Derek J Nunez

Publikováno v: PLoS ONE, Vol 9, Iss 7, p e100778 (2014)

UnlabelledMetformin, a biguanide derivate, has pleiotropic effects beyond glucose reduction, including improvement of lipid profiles and lowering microvascular and macrovascular complications associated with type 2 diabetes mellitus (T2DM). These eff

Externí odkaz: https://doaj.org/article/0210c4a3a2ff4b068af2ccf58d9a2e0f

Zobrazit plný text záznamu

Akademický článek

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Autor: Derek J Nunez, Mark A Bush, David A Collins, Susan L McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow, Paul L Feldman

Publikováno v: PLoS ONE, Vol 9, Iss 4, p e92494 (2014)

GPR119 receptor agonists improve glucose metabolism and alter gut hormone profiles in animal models and healthy subjects. We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-contro

Externí odkaz: https://doaj.org/article/74b4a7893b1c4e2f9bf115e1a0fa43ef

Zobrazit plný text záznamu

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

Autor: Kimberley El, Kyle W. Sloop, Derek J. Nunez, J. L. Brown, Megan E. Capozzi, Jonathan E. Campbell, Sara E. Encisco, Bryanna M. Chazotte, A. Clifford, Berit Svendsen, Sarah M. Gray, Matthew J. Merrins, E. R. Knuth, E. Jin, David A. D'Alessio

Publikováno v: Science Advances

GIPR activity in α cells is required for the complete metabolic response to a meal.
Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4431c39c18c333a410d93c60341384e
http://europepmc.org/articles/PMC7954443

Zobrazit plný text záznamu

Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)

Autor: Derek J. Nunez, David A. D'Alessio

Publikováno v: Diabetes, Obesity and Metabolism. 20:233-237

Glucagon has a noble history in the annals of metabolic disease (1), even though to a layperson insulin is its more famous counter-regulatory partner. For decades medical students have been taught that glucagon raises blood glucose by increasing hepa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d8c4ac4c39faba27788d2e90fd051a
https://doi.org/10.1111/dom.13102

Zobrazit plný text záznamu

Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin

Autor: S. L. Johnson, X. Yao, L. Webster, Jiang Lin, Maciej J. Zamek-Gliszczynski, Ann Louise Walker, Derek J. Nunez, D. S. Gillmor, S. Krug-Gourley, P. Zuo

Publikováno v: Diabetes, Obesity and Metabolism. 18:654-662

Aims To investigate the pharmacodynamics, pharmacokinetics and safety/tolerability of blocking reuptake of bile acids using the inhibitor GSK2330672 (GSK672) in patients with type 2 diabetes (T2D). Methods Subjects with T2D taking metformin were enro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed7dfe91b3d64238f4709549a5789ba9
https://doi.org/10.1111/dom.12656

Zobrazit plný text záznamu

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects

Autor: Derek J. Nunez, Rebecca J. Hodge, R. L. O'Connor-Semmes, Jiang Lin

Publikováno v: Diabetes, Obesity and Metabolism. 17:1007-1010

We investigated the effects of a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist, GSK2374697, on postprandial endogenous total GLP-1 and peptide YY (PYY). Two cohorts of healthy subjects, one normal/overweight and one obese, were rando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666a6305df2381aeaa880629d63c098d
https://doi.org/10.1111/dom.12533

Zobrazit plný text záznamu

GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety

Autor: Susan Andrews, J Chism, Robin L. O'Connor-Semmes, Rebecca J. Hodge, Derek J. Nunez, Allysha Choudhury, Jiang Lin

Publikováno v: Clinical Pharmacology & Therapeutics. 96:704-712

GSK2374697 is a genetically engineered fusion protein of a human domain antibody to exendin-4. This molecule binds with a high affinity to human serum albumin, creating a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist. This study is t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff43b3a11f8fff2981bec6e693198df1
https://doi.org/10.1038/clpt.2014.187

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání